Sort by

Send to

Choose Destination

Search results

Items: 7


Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes.

Truffa AA, Granger CB, White KR, Newby LK, Mehta RH, Hochman JS, Patel MR, Pieper KS, Al-Khalidi HR, Armstrong PW, Lopes RD.

JACC Cardiovasc Interv. 2012 Jul;5(7):769-76. doi: 10.1016/j.jcin.2012.03.018.


Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.

Mills JS, Mahaffey KW, Lokhnygina Y, Nicolau JC, Ruzyllo W, Adams PX, Todaro TG, Armstrong PW, Granger CB; CARDINAL investigators..

Coron Artery Dis. 2012 Mar;23(2):118-25. doi: 10.1097/MCA.0b013e32834e4f8f.


Diagnosing acute myocardial infarction in patients with left bundle branch block.

Lopes RD, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, Granger CB.

Am J Cardiol. 2011 Sep 15;108(6):782-8. doi: 10.1016/j.amjcard.2011.05.006.


Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.

Hudson MP, Armstrong PW, O'Neil WW, Stebbins AL, Weaver WD, Widimsky P, Aylward PE, Ruzyllo W, Holmes D, Mahaffey KW, Granger CB.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):183-92. doi: 10.1161/CIRCOUTCOMES.110.945311.


Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.

Ezekowitz JA, Armstrong PW, Granger CB, Theroux P, Stebbins A, Kim RJ, Patel MR.

Am Heart J. 2010 Aug;160(2):272-8. doi: 10.1016/j.ahj.2010.05.035.


Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study).

Patel MR, Pfisterer ME, Betriu A, Widmisky P, Holmes DR Jr, O'Neill WW, Stebbins A, Van de Werf F, Armstrong PW, Granger CB; APEX-AMI Investigators..

Am J Cardiol. 2009 Jan 15;103(2):181-6. doi: 10.1016/j.amjcard.2008.08.066.


Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.

Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators..

Circulation. 2003 Sep 9;108(10):1184-90.

Items per page

Supplemental Content

Loading ...
Support Center